CD158D抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD158D mouse mAb (green) and negative control (red).    

  
  

CD158D, also known as KIR2DL4 (killer cell immunoglobulin-like receptor 2DL4), is a member of the immunoglobulin-like receptor (KIR) family expressed primarily on natural killer (NK) cells and a subset of T lymphocytes. Discovered in the 1990s, KIR receptors regulate NK cell activity by interacting with human leukocyte antigen (HLA) molecules. Unlike most inhibitory or activating KIRs, KIR2DL4 exhibits dual functionality due to its unique structural features: a single extracellular immunoglobulin domain, a transmembrane region, and a cytoplasmic tail containing both inhibitory (ITIM) and activating motifs. Its primary ligand is HLA-G, a non-classical MHC class I molecule highly expressed in placental trophoblasts, suggesting a critical role in maternal-fetal immune tolerance.

KIR2DL4 signaling is context-dependent. While it can trigger cytokine production (e.g., IFN-γ) via endosomal pathways, it lacks strong cytotoxic activity. This receptor is implicated in pregnancy maintenance, tumor surveillance, and inflammatory responses. Dysregulation of KIR2DL4/HLA-G interactions has been linked to recurrent miscarriage, cancer immune evasion, and autoimmune disorders. CD158D-specific antibodies are vital tools for studying KIR2DL4 expression patterns, functional mechanisms, and therapeutic targeting. Research using these antibodies has advanced our understanding of NK cell biology and potential immunotherapies for cancer, infectious diseases, and reproductive health challenges.